Brief: NeuroStar Advanced Therapy Receives FDA Clearance As First-Line Add-On Treatment For Adolescents With Depression
25/03/2024 14:27
March 25 (Reuters) - Neuronetics Inc STIM.O :
* NEUROSTAR® ADVANCED THERAPY RECEIVES FDA CLEARANCE AS A
FIRST-LINE ADD-ON TREATMENT FOR ADOLESCENTS WITH DEPRESSION
Source text for Eikon: ID:nGNX10mrXF
Further company coverage: STIM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuronetics
See all newsBrief: Neuronetics And Ant Neuro Announce Strategic Collaboration To Integrate Neuronavigation With Neurostar Tms Treatment
Neuronetics Q1 revenue rises 8%, slightly beats estimates
Brief: Neuronetics Inc - Board Reviews Jorey Chernett Letter And Acknowledges Shareholder Engagement
Brief: Neuronetics Inc Initiates Workforce Reduction Impacting Up To 5% Of Employees
Brief: Neuronetics Announces Chief Financial Officer Transition